Variable | 6 Months | 12 Months | ||||
---|---|---|---|---|---|---|
Continence (N = 464) | Incontinence (N = 186) | P value | Continence (N = 512) | Incontinence (N = 138) | P value | |
Age (years) | 65.17 ± 7.33 | 66.73 ± 8.08 | 0.018 | 65.23 ± 7.36 | 67.06 ± 8.22 | 0.012 |
BMI (kg/m2) | 25.05 ± 2.78 | 24.93 ± 3.14 | 0.631 | 25.07 ± 2.84 | 24.82 ± 3.06 | 0.362 |
Comorbidities, no (%) | ||||||
HP | 150 (32.33%) | 68 (36.56%) | 0.302 | 172 (33.59%) | 46 (33.33%) | 0.954 |
DM | 73 (15.73%) | 27 (14.52%) | 0.698 | 80 (15.63%) | 20 (14.49%) | 0.744 |
CHD | 41 (8.84%) | 22 (11.83%) | 0.244 | 46 (8.98%) | 17 (12.32%) | 0.240 |
CD | 12 (2.59%) | 8 (4.30%) | 0.253 | 13 (2.54%) | 7 (5.07%) | 0.126 |
PSA (ng/mL) | 29.15 ± 33.12 | 33.16 ± 38.85 | 0.185 | 29.43 ± 32.66 | 32.51 ± 42.07 | 0.223 |
PV (mL) | 37.14 ± 19.11 | 35.20 ± 19.63 | 0.245 | 36.95 ± 18.75 | 35.24 ± 21.10 | 0.354 |
Gleason score, no (%) | 0.251 | 0.257 | ||||
≤6 | 137 (29.53%) | 56 (30.11%) | 153 (29.88%) | 40 (28.99%) | ||
7 | 178 (38.36%) | 77 (41.40%) | 197 (38.48%) | 58 (42.03%) | ||
≥8 | 133 (28.66%) | 42 (22.58%) | 144 (28.13%) | 31 (22.46%) | ||
Unknown | 16 (3.45%) | 11 (5.91%) | 18 (3.51%) | 9 (6.52%) | ||
Clinical T stage, no (%) | 0.659 | 0.918 | ||||
T1a,b | 2 (0.43%) | 0 | 2 (0.38%) | 0 | ||
T1c | 78 (16.81%) | 36 (19.35%) | 88 (17.19%) | 26 (18.84%) | ||
T2a,b | 178 (38.36%) | 63 (33.87%) | 193 (37.70%) | 48 (34.78%) | ||
T2c | 179 (38.58%) | 79 (42.47%) | 201 (39.26%) | 57 (41.30%) | ||
T3a | 2 (0.43%) | 1 (0.55%) | 2 (0.38%) | 1 (0.73%) | ||
T3b | 25 (5.39%) | 7 (3.76%) | 26 (5.08%) | 6 (4.35%) | ||
OT (mins) | 152.42 ± 44.08 | 154.15 ± 51.17 | 0.666 | 151.66 ± 43.98 | 157.57 ± 53.49 | 0.182 |
NS, no (%) | 97 (20.91%) | 24 (12.90%) | 0.018 | 103 (20.12%) | 18 (13.04%) | 0.058 |
PLND, no (%) | 241 (51.94%) | 97 (52.15%) | 0.961 | 267 (52.15%) | 71 (51.45%) | 0.884 |
DIC (days) | 21.34 ± 11.20 | 20.51 ± 8.00 | 0.356 | 21.37 ± 10.96 | 20.13 ± 7.83 | 0.215 |